Sobi publishes Q2 2025 report: Continued strong portfolio and pipeline momentum

STOCKHOLM, July 16, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the second quarter 2025

Second Quarter 2025

Total revenue increased 13 per cent, 22 per cent at constant exchange rates, (CER)1, to SEK 6,175 M (5,442)

Haematology revenue increased 27 per cent at CER to SEK 4,570 M (3,866), mainly driven by the launch of Altuvoct of SEK 627 M (4), strong sales of Doptelet of SEK 1,220 M (928) and sales of Aspaveli/Empaveli of SEK 304 M (251), somewhat offset by sales of Vonjo of SEK 302 M (347)

Immunology revenue increased 11 per cent at CER to SEK 1,288 M (1,277), driven by strong sales of Gamifant of SEK 632 M (522) and Kineret sales of SEK 749 M (745)

Revenue from the strategic portfolio1* grew by 65 per cent at CER to SEK 3,384 M (2,224)

The adjusted EBITA margin1,2 was 34 per cent (28), excluding items affecting comparability (IAC)2 of SEK -237 M, mainly relating to restructuring costs following organisational changes primarily in the US operations and the R&D functions. EBITA1 was SEK 1,863 M (1,486), corresponding to a margin of 30 per